InterVenn is building unique, powerful liquid-biopsy solutions by leveraging the rich diversity of protein glycosylation.
Glycosylation is the process of attaching sugar molecules to a variety of biological materials such as proteins, lipids and even RNA. Glycosylation is essential for normal cell and organ functions, but alterations have been associated with a variety of diseases including cancer.
InterVenn is decoding the glycoproteome using powerful analytics, and AI-powered software.
InterVenn is the cutting-edge leader for glycoprotein analysis, biomarker research, liquid-biopsy assay development, and new drug target discovery. Our unique platform uses deep learning to automate analysis of a rich field of biomarkers so diverse and complex that it would be otherwise inaccessible.
InterVenn’s unique, powerful liquid biopsy platform is available today.
Our solutions are suitable for a variety of studies - untargeted (discovery) and targeted (quantification), other proof-of-concept initiatives and biomarker development. Together and with a single-blood draw, we can revolutionize disease insights into opportunities for patients. Today.
Get Started Today
Congratulations to InterVenn co-founder Carolyn Bertozzi, Ph.D., for receiving the 2022 Nobel Prize in Chemistry. The Royal Swedish Academy of Sciences recognizes Carolyn for her significant contributions to science.
Read more
2 Tower Place, 5th Floor,
South San Francisco, CA 94080
Bay Area Lab